ArticleJournal of traditional and complementary medicine2025
Kerala Ayurveda Ostoact Tablet treats osteoporosis in ovariectomized rat model via regulating RANKL/OPG pathway.
Article in Journal of traditional and complementary medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and aim: Kerala Ayurveda Ostoact Tablet (OAT) is a traditional Ayurvedic preparation that might use for the management of joint pain, bone pain and arthritis. The goal of present research was to evaluate the activity of OAT in improving postmenopausal osteoporosis (PMO) in ovariectomized (OVX) rats. Experimental procedures: Female rats were ovariectomized bilaterally and distributed into 6 groups (n = 8) as Sham control (SC), Ovariectomy control (OVX), OVX with OAT (50 mg/kg, p.o.), OVX with OAT (100 mg/kg, p.o.) and OVX with OAT (150 mg/kg, p.o.) and Standard group (17β-estradiol, 30 μg/kg, s.c.). SC group rats went through a sham operation procedure. The animals were treated with an oral dose of OAT (50, 100 and 150 mg/kg) for 90 days. Body weight, tail skin temperature (TST) Serum hormones, bone turnover parameters, proinflammatory cytokines, bone physical parameters, histopathological analysis (uterus, vagina, and femur) and microcomputed tomography of the femur were measured on the 90th day of treatment. A new high performance thin layer chromatography (HPTLC) process has been established for the standardization of OAT. Results and conclusion: OVX rats treated with OAT exhibited a significant decrease in TST, improved serum hormonal and lipid profile, bone turnover markers and pro-inflammatory cytokines, bone physical properties, increased bone density, and enhanced cytological and histological alterations with significant improvement in rat's body weight. In addition, OAT administration enhanced the weakening of trabecular bone microarchitecture triggered by OVX confirmed by microcomputed tomography (micro-CT). These findings imply that OAT may help treat osteoporosis in women brought on by menopause.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.